Abstract
Objective: To explore the clinical effect of Mahuang Fuzi and Shenzhuo Decoction on idiopathic membranous nephropathy. Methods: This study is a multicenter, nonrandomized, single-arm clinical trial carried out as per the objective performance criteria, with the target being set at 35.0%. 184 cases of patients suffering from idiopathic membranous nephropathy with Shaoyin Taiyin syndrome were collected. These patients were treated with Mahuang Fuzi and Shenzhuo Decoction with a follow-up period of 3 years. The 24-hour urine protein and blood albumin were observed, and the remission rates of the patients were compared with the target. Results: The mean follow-up time was 18 (12.5, 30) months, and the remission rate was 61.4%, which is a statistically significant difference from the target group of 35%. The remission rates for patients who had and had not used immunosuppressive therapy were 59.6 and 65.5%, respectively, but the difference was not statistically significant (p = 0.254). However, the albumin before the treatment and the course of treatment of the patients was significantly correlated with the disease remission (p < 0.05). However, the albumin before the treatment and the course of treatment of the patients was significantly correlated with the disease remission (p < 0.05). There were no significant changes in renal function before and after treatment, and no severe adverse events occurred during treatment. Conclusion: Mahuang Fuzi and Shenzhuo Decoction have significant effects on idiopathic membranous nephropathy, and has the same effect on patients with membranous nephropathy who are newly treated as well as those who have been treated with immunosuppressive therapy without remission. In addition, the efficacy of this regimen is related to the albumin and the duration of the therapy, but not to 24-hour urine protein or other factors.
Highlights
Idiopathic membranous nephropathy (IMN) is one of the pathological types of primary nephrotic syndrome (NS), with approximately 5–10 patients per million population (Ruggenenti et al, 2017)
2) Patients meeting the diagnostic criteria of Shaoyin Taiyin syndrome in traditional Chinese medicine
A total of 202 IMN patients admitted to the Beijing Hospital of Traditional Chinese Medicine, Shunyi Branch of Beijing Hospital of Traditional Chinese Medicine, Yanqing Hospital of Beijing Hospital of Traditional Chinese Medicine, Tangshan Fengrun Hospital of Traditional Chinese Medicine, and Zhangjiakou Hospital of Traditional Chinese Medicine from September 2016 to January 2019 were selected as the research subjects. 18 patients who had been treated for less than 6 months were not included in the analysis based on clinical experience
Summary
Idiopathic membranous nephropathy (IMN) is one of the pathological types of primary nephrotic syndrome (NS), with approximately 5–10 patients per million population (Ruggenenti et al, 2017). The prevalence of this disease in China is increasing year by year, second only to IgA nephropathy in primary NS (Xu et al, 2016). IST is effective, it has significant toxic side effects, such as those of cyclophosphamide, including hyperglycemia, myelosuppression, infection, infertility, and cancer (van den Brand, 2017) These drugs have a recurrence rate after discontinuation (Fervenza et al, 2017). This study is a multicenter, nonrandomized, single-arm, clinical trial, using the objective performance criteria method to explore the effect of MFSD on idiopathic membranous nephropathy
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
